"People don't often understand how a tiny skin blemish can kill," wrote Sarah Toller in her July 2, 2006 blog entry. Yet it call kill. And it killed Sarah on Tuesday, June 12, 2007.

On June 10, I wrote about Sarah. I wrote about how melanoma was claiming this young woman, how her husband was writing the final chapters of his wife's life on the blog she began just more than one year ago.

I visited Sarah's blog yesterday and read a closing statement written by her beloved. It was simple, to the point, and terrifyingly sad.

A friend of mine with breast cancer just sent out an update e-mail to friends and family. She began her message with an apology for her recent lack of communication. But she assured us all that she's been out of the loop not because she's felt sick or tired. It's because she's been too busy with normal life. And that's a good thing, she says.

This friend wasn't so sure how she would fare -- both physically and emotionally -- when she was first diagnosed with cancer. But she seems to have done a champion's job of rolling with the punches. Sure, she's had ups and downs. But she is overwhelmingly positive and hopeful. And jumping off my computer screen as I read her e-mail were at least seven bits of hope that tell me she is doing just fine despite all that is unbelievably hard about breast cancer.

My friend just had her first infusion of Taxol. A breeze, she calls it. One. So easy on her body -- two -- that she headed right out and took her daughter communion dress shopping. Her little love looked beautiful, she wrote. Like a mini-bride. The mother of the mini-bride then -- three -- turned a sad moment into a comforting one when her daughter asked, "Mommy, who do you think will bring me wedding dress shopping?"

Journalist, commentator, and cancer patient Leroy Sievers -- the guy we've written about before, the guy who has covered many wars and witnessed countless deaths, the guy who is now observing his own death as cancer in his lungs and spine chip away at his life -- has realized that getting good news takes some getting used to.

Sievers got some good news recently. He learned that the new combination of chemotherapy drugs he's been receiving has shrunk the tumors in his lungs. And scans show the tumor on his spine is healing. It's taken him days to truly understand this concept -- this concept of hope that has miraculously delivered him more time. He didn't expect it.

Sievers fully expected that he would soon be dead. That's why he's been savoring the cold, crisp fall days -- because he was not certain he would ever see such a season. He was sure he would never host another Halloween party either -- a party he canceled this year due to his health. But now, as he takes in this new sensation of hope, he considers the possibility he may be around for another party. And he thinks he'll dress up as a tumor. Halloween is one time when good taste is never important, he says.

Sievers, who offers a weekly personal health update for NPR, available in print or in podcast format on his blog, plans to keep living in the moment. He doesn't want to overdo this hope thing. So right now, he is simply enjoying the colorful leaves -- and the season he calls one of his favorites.

The power of positivity is subjective when it comes to cancer survival. There are those who argue that keeping up a positive attitude puts too much pressure on cancer patients. I think it depends on who you are at the time of cancer diagnosis, and what your individual personality style is in facing adversity, that is far more relevant to being a survivor.

Last Wednesday, when the news broke that Farrah Fawcett had been diagnosed with cancer, she asked that her privacy be respected. As is the case with most celebrities, it was not likely to happen. We have seen almost constant coverage in the details of her cancer diagnosis and treatment, and the paparazzi have captured in photographs her every movement.

According to Breast Cancer UK, maintaining a healthy weight is one of the best ways to reduce the risk of developing cancer. The organization is featuring the efforts of three women and one man as they chronicle their progress in the Ten Top Tips ten week weight loss program.

Led by specialist dietician Weight Concern Alison Chipperfield, the four volunteers Liz Ainsworth, Emma Russell, Stacey Delaney and Mike Chapman will share the personal efforts of losing weight with diet and lifestyle changes in reaching a greater level of health. To follow the weekly updates, visit Ten Top Tips Reduce the Risk.

Cancer Research UK also features a Healthy Eating area of the organization's website highlighting comprehensive information and resources in cancer prevention through diet and healthy eating tips.

According to Cancer Research UK, "Experts think that about a quarter of all cancer deaths are caused by unhealthy diets and obesity. Our diet influences our risk of many cancers, including cancers of the colon, stomach, and breast. You can reduce your cancer risk by eating a healthy, balanced diet that is high in fiber, fruit and vegetables, and low in red and processed meat and saturated fat."

Through support in funding, Cancer Research UK is involved in the EPIC study. The study -- called the European Prospective Investigation into Cancer and Nutrition (EPIC) -- is an enormous undertaking involving 521,483 individuals in 10 different European countries. EPIC is unique because the populations being tracked are so diverse in eating habits. But this is precisely what gives the study the advantage it has in making comparisons and noting trends.

Reuters has just issued an update on Eli Lilly's announcement that the U.S. Food and Drug Administration, FDA, approved the use of Gemzar in the treatment of recurrent ovarian cancer, questioning why the company omitted information that the FDA approval goes against the advice of an FDA advisory panel earlier this year that strongly recommended against approval of the drug for this use.

The FDA approved use of Gemzar in combination with carboplatin, in chemotherapy treatment for women with advanced ovarian cancer that has relapsed at least six months after initial therapy. The reason the FDA advisory panel voted against the approval of the use of Gemzar in combination with carboplatin, were due to questions raised about Lilly's trial data and the way the company conducted the 356-person clinical study. The panel was concerned that patients in the late-stage clinical trial failed to survive longer than those taking carboplatin alone. The FDA went ahead and approved it after the drug company provided additional information.

What needs to be made clear is that Gemzar does not seem to prolong the life of women with recurrent ovarian cancer, and the drug company is only stating that Gemzar provides longer progression-free survival than patients taking carboplatin alone. Progression-free survival measures the time before the disease recurs or worsens.

According to Reuters, when a spokesperson for Lilly was asked why they did not mention in its release that the FDA advisory panel had voted against the approval of Gemzar, or the drug's failure to prolong life, he said, "I'm not sure that needed to be the focus."